Financial Comparison: ZIOPHARM Oncology (NASDAQ:ZIOP) versus Its Competitors

ZIOPHARM Oncology (NASDAQ: ZIOP) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare ZIOPHARM Oncology to similar businesses based on the strength of its earnings, dividends, profitability, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

40.2% of ZIOPHARM Oncology shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.4% of ZIOPHARM Oncology shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ZIOPHARM Oncology and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ZIOPHARM Oncology $6.86 million -$165.29 million -8.25
ZIOPHARM Oncology Competitors $290.27 million $35.99 million 53.69

ZIOPHARM Oncology’s peers have higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares ZIOPHARM Oncology and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ZIOPHARM Oncology -818.19% N/A -47.07%
ZIOPHARM Oncology Competitors -5,713.56% -84.24% -35.59%

Risk and Volatility

ZIOPHARM Oncology has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, ZIOPHARM Oncology’s peers have a beta of 2.51, indicating that their average share price is 151% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for ZIOPHARM Oncology and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIOPHARM Oncology 0 2 2 0 2.50
ZIOPHARM Oncology Competitors 954 3405 11909 239 2.69

ZIOPHARM Oncology currently has a consensus target price of $16.50, indicating a potential upside of 284.62%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.53%. Given ZIOPHARM Oncology’s higher possible upside, research analysts plainly believe ZIOPHARM Oncology is more favorable than its peers.


ZIOPHARM Oncology peers beat ZIOPHARM Oncology on 10 of the 13 factors compared.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with's FREE daily email newsletter.

Leave a Reply